Last updated: July 30, 2026
BOEHRINGER INGELHEIM PHARMACEUTICALS v. SUN PHARMACEUTICALS (3:17-cv-08819): Litigation Summary, Claims, and Exclusivity/IP Risk Assessment
Executive summary: The docket 3:17-cv-08819 reflects patent litigation filed by Boehringer Ingelheim Pharmaceuticals, Inc. against Sun Pharmaceutical Industries Ltd. The case record provides insufficient actionable, case-specific details in the available input to accurately summarize the asserted patents, claim construction, infringement theories, procedural posture, or settlement/exit outcomes.
Because a complete and accurate litigation analysis requires verified, case-specific information (patent numbers asserted, FDA Orange Book/RLD ties, complaint and answer dates, Markman orders, dispositive rulings, and final outcomes), no partial or generalized account can be produced without risking factual errors.
What patents were asserted in Boehringer Ingelheim v. Sun Pharmaceuticals 3:17-cv-08819?
Featured-snippet answer: Not provided in the input.
Which patent numbers and expiration dates drive the case?
Featured-snippet answer: Not provided in the input.
What drug and FDA reference product were the patents tied to?
Featured-snippet answer: Not provided in the input.
Were claims method-of-use, formulation, or manufacturing?
Featured-snippet answer: Not provided in the input.
What is the procedural posture in 3:17-cv-08819 (motions, claim construction, trial)?
Featured-snippet answer: Not provided in the input.
What were the key deadlines (case management, Markman, dispositive motions)?
Featured-snippet answer: Not provided in the input.
Did the court issue a claim construction order or summary judgment?
Featured-snippet answer: Not provided in the input.
Was the case dismissed, stayed, or resolved by settlement?
Featured-snippet answer: Not provided in the input.
How do paragraph IV or Orange Book events connect to this litigation?
Featured-snippet answer: Not provided in the input.
Was Sun’s filing a generic ANDA with a paragraph IV certification?
Featured-snippet answer: Not provided in the input.
What Orange Book patents were listed for the reference listed drug?
Featured-snippet answer: Not provided in the input.
What was the FDA timeline impact (30-month stay, dismissal triggers)?
Featured-snippet answer: Not provided in the input.
What infringement theories did Boehringer Ingelheim plead against Sun?
Featured-snippet answer: Not provided in the input.
Which product(s) were accused (ANDA strengths/dosage forms)?
Featured-snippet answer: Not provided in the input.
What elements were targeted (use, composition, process)?
Featured-snippet answer: Not provided in the input.
What defenses did Sun raise in 3:17-cv-08819?
Featured-snippet answer: Not provided in the input.
Was validity contested (anticipation/obviousness/indefiniteness)?
Featured-snippet answer: Not provided in the input.
Was non-infringement argued via design-around or non-equivalence?
Featured-snippet answer: Not provided in the input.
What did claim construction change in this case (if any)?
Featured-snippet answer: Not provided in the input.
Did the court narrow or expand key claim terms?
Featured-snippet answer: Not provided in the input.
How did the construed terms affect infringement/validity outcomes?
Featured-snippet answer: Not provided in the input.
What was the outcome of the case and what does it mean for generic launch risk?
Featured-snippet answer: Not provided in the input.
Did Sun launch at risk or wait for final resolution?
Featured-snippet answer: Not provided in the input.
What remaining enforceable patents could block market entry?
Featured-snippet answer: Not provided in the input.
Key Takeaways
- The docket identifier 3:17-cv-08819 is provided, but asserted patents, accused product, procedural events, rulings, and resolution terms are not included in the input, preventing a complete and accurate litigation summary.
FAQs
- What is the case caption structure and parties’ roles in 3:17-cv-08819?
- Which patents were listed in the Orange Book for the reference product at issue?
- Did Sun file an ANDA with paragraph IV certifications tied to the asserted patents?
- What outcomes (dismissal, settlement, or judgment) are reported in the docket for 3:17-cv-08819?
- How does the case affect expected generic launch timing for the drug at issue?
References (APA)
- 3:17-cv-08819 Boehringer Ingelheim Pharmaceuticals, Inc. v. Sun Pharmaceutical Industries Ltd. (U.S. District Court docket).
